爱尔兰爵士制药的defiteli有什么副作用？

Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and defibrotide () is a drug used to treat hepatic veno-occlusive disease.

Defiteli is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defiteli can act on these receptors to produce a variety of downstream effects. Defibrotide can also reduce the expression of cell adhesion molecules on the surface of endothelial cells, thereby reducing the adhesion of leukocytes to vascular endothelial cells and reducing the inflammatory damage of endothelial cells.

What are the side effects of Irish Jazz Pharmaceuticals' Defiteli?

The most common side effects (incidence ≥10% and independently causal) with treatment with defiteli are hypotension, diarrhea, vomiting, nausea, and epistaxis.

The incidence of grade 3-4 reactions related to defiteli was 7%, mainly hypotension, pulmonary and gastrointestinal bleeding, and abdominal cramps. Only 4% of patients discontinued treatment due to side effects.

It is important to note that defiteli may enhance the pharmacodynamic activity of antithrombotic/fibrinolytic agents such as heparin or alteplase.

The side effects of defibrotide () are usually mild and patients do not need to worry too much.

Recommended related hot articles: /newsDetail/95254.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.